MiniMed Group Inc (NASDAQ:MMED) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

MiniMed Group Inc (NASDAQ:MMED) has earned an average recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $21.6667.

A number of equities analysts recently issued reports on the stock. Wall Street Zen upgraded shares of MiniMed Group to a “hold” rating in a research note on Saturday, March 14th. The Goldman Sachs Group assumed coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They issued a “buy” rating and a $24.00 price target on the stock. Zacks Research upgraded shares of MiniMed Group to a “hold” rating in a research note on Thursday, April 9th. Morgan Stanley assumed coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They issued an “overweight” rating and a $19.00 price target on the stock. Finally, BTIG Research assumed coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They issued a “buy” rating and a $25.00 price target on the stock.

MiniMed Group Trading Up 0.1%

MiniMed Group stock opened at $10.89 on Wednesday. The stock has a 50 day moving average of $14.08. MiniMed Group has a twelve month low of $10.65 and a twelve month high of $20.48.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.